Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT

Zhu, Haiyan; Tao, Xuejiao; Zhou, Lulu; Sheng, Bo; Zhu, Xuejie; Zhu, Xueqiong

doi:10.1186/s12885-019-6046-x

Cited by 16 publications

(10 citation statements)

References 27 publications

(43 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[177] Cervical squamous cell carcinoma High expression of TRX1 is associated with poor response to cisplatin-based neoadjuvant chemotherapy. [178] Cholangiocarcinoma TRX is overexpressed in tumor tissue and in dysplastic bile ducts with highly abnormal growth patterns. [150] Clear cell renal cell carcinoma TXNDC5 is overexpressed in tumor tissues compared to adjacent normal tissues.…”

Section: Tumor Typementioning

confidence: 99%

The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies

et al. 2020

View full text Add to dashboard Cite

Cancer remains an elusive, highly complex disease and a global burden. Constant change by acquired mutations and metabolic reprogramming contribute to the high inter- and intratumor heterogeneity of malignant cells, their selective growth advantage, and their resistance to anticancer therapies. In the modern era of integrative biomedicine, realizing that a personalized approach could benefit therapy treatments and patients’ prognosis, we should focus on cancer-driving advantageous modifications. Namely, reactive oxygen species (ROS), known to act as regulators of cellular metabolism and growth, exhibit both negative and positive activities, as do antioxidants with potential anticancer effects. Such complexity of oxidative homeostasis is sometimes overseen in the case of studies evaluating the effects of potential anticancer antioxidants. While cancer cells often produce more ROS due to their increased growth-favoring demands, numerous conventional anticancer therapies exploit this feature to ensure selective cancer cell death triggered by excessive ROS levels, also causing serious side effects. The activation of the cellular NRF2 (nuclear factor erythroid 2 like 2) pathway and induction of cytoprotective genes accompanies an increase in ROS levels. A plethora of specific targets, including those involved in thioredoxin (TRX) and glutathione (GSH) systems, are activated by NRF2. In this paper, we briefly review preclinical research findings on the interrelated roles of the NRF2 pathway and TRX and GSH systems, with focus given to clinical findings and their relevance in carcinogenesis and anticancer treatments.

show abstract

Section: Tumor Typementioning

confidence: 99%

The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies

et al. 2020

View full text Add to dashboard Cite

show abstract

“…These values were relatively high compared to previously reported values for other protein cancer biomarker tests, which ranged from 60-90% [21][22][23]. [34][35][36][37][38][39]. However, most of the studies were carried out in cancer cells or tissue not in blood, and focused on the gene expression level of Trx1.…”

Section: Discussionmentioning

confidence: 74%

The Blood level of Thioredoxin 1 as a Supporting Biomarker in the Detection of Breast Cancer

Lee

Kim²,

Choi

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: It has been a long-time unmet need to have a means to detect breast cancer (BC) using blood. Although mammography is accepted as the gold standard for screening, thus, playing a role to reduce death from breast cancer, a blood-based diagnostic can complement mammography and assist in the accurate diagnosis of BC. We have previously reported the possible use of thioredoxin 1 (Trx1) in serum as a novel means to detect BC. In the present study, we validated the clinical utility of Trx1 to detect BC by testing sera from biopsy-confirmed cancer patients, and normal healthy people.Methods: We have generated monoclonal antibodies against Trx1 and developed an ELISA kit that can quantitate Trx1 in sera. The level of Trx1 was determined in each serum from normal healthy women (n=114), as well as patients with BC (n=106), and other types of cancers (n=74) including cervical, lung, stomach, colorectal, and thyroid cancer. The sera from BC patients were collected according to their age and cancer stage. Several pathological and molecular aspects of BC were analyzed along with the Trx1 levels of BC patients. Test results were compared to those from mammography. Each test was duplicated, and test results were analyzed by ROC analysis, one-way ANOVA tests, and unpaired t-tests.Results: The mean level of Trx1 from normal women’s sera was 5.45±4.16 (±SD) U/ml and that from BC was 21.96±6.79 U/ml. The difference between these two values was large enough to distinguish BC sera from healthy sera with a sensitivity of 94.3% and specificity of 94.7% (AUC 0.985, p<0.0001). Most Trx1 levels from BC patients’ sera were higher than the cut-off value of 14.13 Unit/ml regardless of age, stage, histological grade, type, and specific receptors’ expression profile of BC. The blood levels of Trx1 from the group of patients with other types of cancers (2.70±2.01 U/ml) was low to be distinguishable from BC. Trx1 level could rescue most of misreading incompleteness of mammography. Conclusion: These results indicated that the blood level of Trx1 could be an effective and accurate means to assist or complement current BC diagnostic modalities.

show abstract

“…Even though the sample numbers of certain other types of cancer were insufficient, it still provides important clues about what could be expected from those other types of cancer. It should be acknowledged that there is a pile of reports showing increased expression of Trx1 in various types of cancer [ 30 – 35 ]. However, most of the studies were carried out in cancer cells or tissue, not in blood, and focused on the gene expression level of Trx1.…”

Section: Discussionmentioning

confidence: 99%

The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer

et al. 2022

View full text Add to dashboard Cite

Background There is a long-time unmet need for a means to detect breast cancer (BC) using blood. Although mammography is accepted as the gold standard for screening, a blood-based diagnostic can complement mammography and assist in the accurate detection of BC in the diagnostic process period of early diagnosis. We have previously reported the possible use of thioredoxin 1 (Trx1) in serum as a novel means to detect BC. In the present study, we validated the clinical utility of Trx1 to identify BC by testing sera from biopsy-confirmed cancer patients and women without cancer. Methods We have generated monoclonal antibodies against Trx1 and developed an ELISA kit that can quantitate Trx1 in sera. The level of Trx1 was determined in each serum from women without cancer (n = 114), as well as in serum from patients with BC (n = 106) and other types of cancers (n = 74), including cervical, lung, stomach, colorectal, and thyroid cancer. The sera from BC patients were collected and classified by the subjects’ age and cancer stage. In addition to the Trx1 levels of BC patients, several pathological and molecular aspects of BC were analyzed. Test results were retrospectively compared to those from mammography. Each test was duplicated, and test results were analyzed by ROC analysis, one-way ANOVA tests, and unpaired t-tests. Results The mean level of Trx1 from women without cancer was 5.45 ± 4.16 (±SD) ng/ml, that of the other malignant cancer patient group was 2.70 ± 2.01 ng/ml, and that from the BC group was 21.96 ± 6.79 ng/ml. The difference among these values was large enough to distinguish BC sera from non-BC control sera with a sensitivity of 97.17% and specificity of 94.15% (AUC 0.990, p < 0.0001). Most Trx1 levels from BC patients’ sera were higher than the cut-off value of 11.4 ng/ml regardless of age, stage, histological grade, type, and specific receptors’ expression profile of BC. The level of Trx1 could rescue women from most cases of misread or incomplete mammography diagnoses. Conclusion These results indicated that the blood level of Trx1 could be an effective and accurate means to assist the detection of BC during the early diagnosis period.

show abstract

Expression of thioredoxin 1 and peroxiredoxins in squamous cervical carcinoma and its predictive role in NACT

Cited by 16 publications

References 27 publications

The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies

The NRF2, Thioredoxin, and Glutathione System in Tumorigenesis and Anticancer Therapies

The Blood level of Thioredoxin 1 as a Supporting Biomarker in the Detection of Breast Cancer

The blood level of thioredoxin 1 as a supporting biomarker in the detection of breast cancer

Contact Info

Product

Resources

About